argenx SE (NASDAQ:ARGX) Q2 2020 Earnings Conference Call - Final Transcript

Jul 30, 2020 • 08:30 am ET


argenx SE (NASDAQ:ARGX) Q2 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Welcome to argenx Half Year 2020 Financial Results and Second Quarter Business Update Conference Call. [Operator Instructions] To follow the presentation, we ask that you navigate the slides as directed by argenx management. [Operator Instructions]

I would now like to Beth DelGiacco, Vice President of Investor Relations at argenx. Thank you.

Beth DelGiacco

Thank you. A press release was issued earlier today with our half year 2020 financial results and second quarter business update. This can be found on our website along with the presentation for today's webcast. Before we begin, I'd like to remind you on slide two that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical development, regulatory time lines, the potential success of our product candidates, financial projections and upcoming milestones. Actual results may differ materially from those indicated by these statements. Our genus is not under any obligation to update statements regarding the future or to conform those statements in relation to actual results unless required by law. I'm joined on the call today by Tim Van Hauwermeiren, Chief Executive Officer; Keith Woods, Chief Operating Officer; and Eric Castaldi, Chief Financial Officer. On slide three, you can see our agenda. Tim will be highlighting recent milestones, including the positive Phase III ADAPT data we reported in May and the progress we've made in our ongoing efgartigimod programs and additional indications. We announced a change in our development plan for cusatuzumab this morning, and Tim will update you on the reason for that shift in strategy. And he will close with an update on our earlier stage programs, including those that are wholly owned and partnered. Keith will then provide an update on our commercial preparation, and Eric will share our financial results. We will then close with a Q&A session.

I will now turn the call over to Tim.

Tim Van Hauwermeiren

Thank you, Beth, and welcome, everyone. We appreciate you joining the call today. We are now almost six months into what we can only continue to describe as unprecedented times. I hope you and your families are staying safe and healthy. At argenx, we have been opening our organic offices on a restricted basis as we watch the data on the number of coronavirus cases in Belgium. We continue to keep our work from home mandate in the U.S. and Japan. Throughout this virtual work environment, our team has kept to its high work standards to minimize disruptions to our business as best as possible. For this, I must share my gratitude to the entire team in navigating this new normal. On slide four, I would like to highlight some of the significant milestones we have achieved virtually as a team all of which will be covered in more detail later in the call. We executed a key Phase III data disclosure with the top line readout of our ADAPT trial, including a subsequent financing to support our first commercial launch and the advancement of our differentiated pipeline. The data from